Advisor – Rna-lnp Process Development – Br&d

Eli Lilly Eli Lilly · Pharma · Boston, MA

This role focuses on the process development and engineering of genetic medicines, specifically RNA-lipid nanoparticles (LNPs) and oligonucleotide drug products, for parenteral formulations. The position involves building process capabilities, assessing and mitigating scale-up risks, collaborating across functions, and supporting regulatory filings within the pharmaceutical industry.

What you'd actually do

  1. Build process capabilities for lab scale, early phase clinical scale, and scale up technologies for RNA-LNPs and other parenteral drug products.
  2. Support the development of portfolio assets (particularly RNA-LNPs), including assessing and mitigating process risks during scale-up through an understanding of in-process and final product critical quality attributes. Anticipate and manage increased workload during scale-up and GMP readiness phases.
  3. Work with project management and other technical leaders to execute complex tech transfer challenges across sites, including both internal and external manufacturing organizations. Help oversee supply chain readiness and ensure integration of novel excipients into regulatory filing packages.
  4. Implement processes to deliver drug product material for clinical trials and support generating data required for regulatory filings, including addressing CMC regulatory questions.
  5. Ensure consistency in technical deliverables and documentation across transfers.

Skills

Required

  • Ph.D. in Chemical Engineering, Biomedical Engineering, Chemistry, Pharmaceutical Sciences, or a related field.
  • Experience with process development of RNA-lipid nanoparticle and/or oligonucleotide formulations.
  • Familiarity with engineering fundamentals towards designing and optimizing manufacturing processes, or drug delivery platforms including RNAs and LNPs.

Nice to have

  • Hands-on experience working with process equipment from lab to pilot scales is preferred.
  • Previous experience with regulatory submissions of RNA-based therapies is preferred.
  • Self-directed and highly motivated individual who wants to learn new techniques while continually pursuing research and publication goals.
  • Excellent communicator (oral and written) with presentation experience, along with a strong publication record.
  • Proficient in data analysis and reporting.

What the JD emphasized

  • process development of RNA-lipid nanoparticle and/or oligonucleotide formulations